Markets:

Overview

News

Currencies

International

Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

110.27 -0.64 (-0.58%)

Streaming Delayed Price Updated: 11:57 AM EST, Jan 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

December 23, 2024

From Glaukos Corporation

Via Business Wire

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

December 17, 2024

From Glaukos Corporation

Via Business Wire

Wall Street's Top 10 Stock Calls This Week - Saturday, Dec. 7 ↗

December 07, 2024

What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Dec. 2-6, 2024.

Via Talk Markets

Topics Stocks / Equities

This Constellation Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

December 06, 2024

Via Benzinga

How Is The Market Feeling About Glaukos? ↗

December 03, 2024

Via Benzinga

Analyst Scoreboard: 5 Ratings For Glaukos ↗

November 26, 2024

Via Benzinga

How Is The Market Feeling About Glaukos? ↗

October 30, 2024

Via Benzinga

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos ↗

December 02, 2024

Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.

Via Benzinga

This Kohl's Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗

December 02, 2024

Via Benzinga

Glaukos Announces Participation in Upcoming Investor Conferences

November 08, 2024

From Glaukos Corporation

Via Business Wire

Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds ↗

November 05, 2024

Glaukos Corporation's Q3 revenue grew 24% to $96.7 million, beating estimates, with an EPS loss of $(0.28). 2024 sales guidance raised despite anticipated headwinds.

Via Benzinga

A Closer Look at 7 Analyst Recommendations For Glaukos ↗

October 14, 2024

Via Benzinga

Navigating 11 Analyst Ratings For Glaukos ↗

August 28, 2024

Via Benzinga

Glaukos Stock: A Deep Dive Into Analyst Perspectives (12 Ratings) ↗

August 01, 2024

Via Benzinga

Glaukos Announces Third Quarter 2024 Financial Results

November 04, 2024

From Glaukos Corporation

Via Business Wire

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

October 16, 2024

From Glaukos Corporation

Via Business Wire

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting

October 14, 2024

From Glaukos Corporation

Via Business Wire

10 Analysts Have This To Say About Glaukos ↗

July 10, 2024

Via Benzinga

Deep Dive Into Glaukos Stock: Analyst Perspectives (12 Ratings) ↗

May 22, 2024

Via Benzinga

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4

October 09, 2024

From Glaukos Corporation

Via Business Wire

Glaukos Announces Participation in Upcoming Investor Conferences

August 16, 2024

From Glaukos Corporation

Via Business Wire

Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday ↗

August 01, 2024

Via Benzinga

GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q2 2024 ↗

July 31, 2024

GKOS stock results show that Glaukos missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Via InvestorPlace

Glaukos Announces Second Quarter 2024 Financial Results

July 31, 2024

From Glaukos Corporation

Via Business Wire

7 Leading MedTech Stocks for Next-Gen Health Solutions ↗

July 31, 2024

With healthcare innovations promising to deliver groundbreaking solutions, these MedTech stocks should be on your radar.

Via InvestorPlace

This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗

July 10, 2024

Via Benzinga

Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31

July 10, 2024

From Glaukos Corporation

Via Business Wire

Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock

June 14, 2024

From Glaukos Corporation

Via Business Wire

Glaukos Announces Participation in Upcoming Investor Conferences

May 28, 2024

From Glaukos Corporation

Via Business Wire

Eye Disease-Focused Glaukos' 'Investor Interest Should Continue To Gain Momentum:' Analyst ↗

May 02, 2024

Glaukos reports Q1 adjusted EPS loss, sales beat estimates. Strong guidance for 2024 with positive analyst sentiment, driving stock up 6.22%.

Via Benzinga

Topics Earnings

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.